STAT3 and breast carcinoma: Bioactivity of the rhOSM was comparable to commercially available recombinant human OSM (chOSM) in human breast cancer cells as determined by an enzyme-linked immunosorbent assay (ELISA), which detected phosphorylation of STAT3.